Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in phase III clinical trials

Arthritis Care and Research

Volumn 65, Issue 2, 2013, Pages 309-313

  Hsia, Elizabeth C ^a,b   Cush, John J ^c   Matteson, Eric L ^a   Beutler, Anna ^d,e   Doyle, Mittie K ^d   Hsu, Benjamin ^d   Xu, Stephen ^d   Rahman, Mahboob U ^d,f  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BAYLOR RESEARCH INSTITUTE   (United States)

^d Mayo Clinic   (United States)

^e ALEXION PHARMACEUTICALS   (United States)

^f PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GOLIMUMAB; ISONIAZID; METHOTREXATE; PREDNISONE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DISEASE DURATION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LATENT TUBERCULOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SCREENING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTITUBERCULAR AGENTS; ARTHRITIS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; RECURRENCE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84873197989     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21788     Document Type: Article

References (9)

1. Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010; 69 Suppl: i2-29.
2. Cellestis. QuantiFERON-TB Gold clinicians guide and QuantiFERON-TB Gold In-Tube method package insert. URL: www.cellestis.com.
3. Oxford Immunotec. T-SPOT.TB. URL: http://www.oxfordimmunotec.com/T-SPOT- International.
4. Hsia EC, Schluger N, Cush JJ, Chaisson RE, Matteson EL, Xu S, et al. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 2012; 64: 2068-77.
5. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al, on behalf of the BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-72.
6. Gomez-Reino JJ, Carmona L, Descalzo MA, for the BIOBADASER Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-61.
7. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al, for the START Study Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006; 54: 1075-86.
8. Lobue P, Menzies D,. Treatment of latent tuberculosis infection: an update. Respirology 2010; 15: 603-22.
9. Hanta I, Ozbek S, Kuleci S, Sert M, Kocabas A,. Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFα. Clin Rheumatol 2007; 26: 1867-70.